Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Nucleic Acid Ther ; 29(5): 231-244, 2019 10.
Article in English | MEDLINE | ID: mdl-31393218

ABSTRACT

Small interfering RNAs (siRNAs) conjugated to N-acetylgalactosamine (GalNAc) ligands have been used to treat disease in patients. However, conjugates with other ligands deliver siRNA less efficiently, limiting the development of new targeted therapies. Most approaches to enhancing the potency of such conjugates have concentrated on increasing ligand effectiveness and/or the chemical stability of the siRNA drug. One complementary and unexplored alternative is to increase the number of siRNAs delivered per ligand. An ideal system would be a single chemical entity capable of delivering multiple copies of an oligonucleotide drug and/or several such drugs simultaneously. Here we report that siRNAs can be stably linked together under neutral aqueous conditions to form chemically defined siRNA "multimers," and that these multimers can be delivered in vivo by a GalNAc ligand. Conjugates containing multiple copies of the same siRNA showed enhanced activity per unit of ligand, whereas siRNAs targeting different genes linked to a single ligand facilitated multigene silencing in vivo; this is the first demonstration of silencing several genes simultaneously in vivo using ligand-directed multimeric siRNA. Multimeric oligonucleotides represent a powerful and practical new approach to improve intracellular conjugate delivery.


Subject(s)
Biological Transport/genetics , Gene Silencing , Genetic Therapy/trends , RNA, Small Interfering/therapeutic use , Acetylgalactosamine/genetics , Acetylgalactosamine/pharmacology , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Ligands , Oligonucleotides/genetics , Oligonucleotides/therapeutic use , RNA, Double-Stranded , RNA, Small Interfering/genetics
SELECTION OF CITATIONS
SEARCH DETAIL